Non-invasive diagnosis is a procedure of identifying a disease without or with minimal incision of the body. These methods involve different techniques such as identifying genetic structure, biomarkers, changes in molecular biology, along with imaging technologies. Cancer is a disease related to genetic alteration of the cells and therefore causing uncontrolled growth and forming tumor like structure. Imaging is the preferred method of cancer detection but cannot have genetic access; on the other hand biopsies which have genetic access are complicated and difficult to perform repetitively during the course of cancer diagnosis and therapy. Therefore newer techniques developed in lines with non invasive diagnosis such as molecular diagnosis, serum based immunoassays and chemical tests to identify chemical components in the body especially from blood and urine. All these procedures are performed either with non-surgical or minimal surgical procedures; therefore these non-invasive cancer diagnostic techniques are becoming more and more popular among healthcare practitioners.

The global Noninvasive Cancer Diagnostics market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Noninvasive Cancer Diagnostics in various end use industries. The expanding demands from the Solid Tumors, Blood Cancer, Lung Cancer and Breast Cancer, are propelling Noninvasive Cancer Diagnostics market. Clinical Chemistry, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Immunochemistry/Immunoassay segment is estimated at % CAGR for the next seven-year period.

The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Objectives

This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Noninvasive Cancer Diagnostics, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.

Key Features of The Study:

This report provides in-depth analysis of the global Noninvasive Cancer Diagnostics market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.

This report profiles key players in the global Noninvasive Cancer Diagnostics market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Noninvasive Cancer Diagnostics sales data, market share and ranking.

This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.

This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.

Key companies of Noninvasive Cancer Diagnostics covered in this report include Precision Therapeutics, Inc. (U.S.), A&G Pharmaceutical, Inc. (U.S.), Affymetrix Inc. (U.S.), AVIVA Biosciences Corporation (U.S.), BIOVIEW Inc. (U.S.), Laboratory Corporation of America Holdings (LabCorp) (U.S.), Quest Diagnostics Incorporated Cancer Genetics Inc. (U.S.), Digene Corporation (U.S.) and Gen-Probe Incorporated (U.S.), etc.

The global Noninvasive Cancer Diagnostics market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.

Market Segmentation

Company Profiles:

Precision Therapeutics, Inc. (U.S.)

A&G Pharmaceutical, Inc. (U.S.)

Affymetrix Inc. (U.S.)

AVIVA Biosciences Corporation (U.S.)

BIOVIEW Inc. (U.S.)

Laboratory Corporation of America Holdings (LabCorp) (U.S.)

Quest Diagnostics Incorporated Cancer Genetics Inc. (U.S.)

Digene Corporation (U.S.)

Gen-Probe Incorporated (U.S.)

IVDiagnostics, Inc. (U.S.)

Scope of Noninvasive Cancer Diagnostics - Market Report

Report Metric	Details
Report Name	Noninvasive Cancer Diagnostics - Market
CAGR	5%
Global Noninvasive Cancer Diagnostics market, by region:	North America (U.S., Canada, Mexico) Europe (Germany, France, UK, Italy, etc.) Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.) South America (Brazil, etc.) Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Noninvasive Cancer Diagnostics market, Segment by Type:	Clinical Chemistry Immunochemistry/Immunoassay Molecular Diagnostics Others
Global Noninvasive Cancer Diagnostics market, by Application	Solid Tumors Blood Cancer Lung Cancer Breast Cancer Others
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Noninvasive Cancer Diagnostics companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion

FAQ for this report

What are the Application segmentation covered in the Noninvasive Cancer Diagnostics - Market report?

Ans: The Applications covered in the Noninvasive Cancer Diagnostics - Market report are Solid Tumors, Blood Cancer, Lung Cancer, Breast Cancer, Others

What are the Type segmentation covered in the Noninvasive Cancer Diagnostics - Market report?

Ans: The Types covered in the Noninvasive Cancer Diagnostics - Market report are Clinical Chemistry, Immunochemistry/Immunoassay, Molecular Diagnostics, Others

1 Market Overview of Noninvasive Cancer Diagnostics

1.1 Noninvasive Cancer Diagnostics Market Overview

1.1.1 Noninvasive Cancer Diagnostics Product Scope

1.1.2 Noninvasive Cancer Diagnostics Market Status and Outlook

1.2 Global Noninvasive Cancer Diagnostics Market Size Overview by Region 2018 VS 2022 VS 2029

1.3 Global Noninvasive Cancer Diagnostics Market Size by Region (2018-2029)

1.4 Global Noninvasive Cancer Diagnostics Historic Market Size by Region (2018-2023)

1.5 Global Noninvasive Cancer Diagnostics Market Size Forecast by Region (2024-2029)

1.6 Key Regions, Noninvasive Cancer Diagnostics Market Size (2018-2029)

1.6.1 North America Noninvasive Cancer Diagnostics Market Size (2018-2029)

1.6.2 Europe Noninvasive Cancer Diagnostics Market Size (2018-2029)

1.6.3 Asia-Pacific Noninvasive Cancer Diagnostics Market Size (2018-2029)

1.6.4 Latin America Noninvasive Cancer Diagnostics Market Size (2018-2029)

1.6.5 Middle East & Africa Noninvasive Cancer Diagnostics Market Size (2018-2029)

2 Noninvasive Cancer Diagnostics Market by Type

2.1 Introduction

2.1.1 Clinical Chemistry

2.1.2 Immunochemistry/Immunoassay

2.1.3 Molecular Diagnostics

2.1.4 Others

2.2 Global Noninvasive Cancer Diagnostics Market Size by Type: 2018 VS 2022 VS 2029

2.2.1 Global Noninvasive Cancer Diagnostics Historic Market Size by Type (2018-2023)

2.2.2 Global Noninvasive Cancer Diagnostics Forecasted Market Size by Type (2024-2029)

2.3 Key Regions Market Size by Type

2.3.1 North America Noninvasive Cancer Diagnostics Revenue Breakdown by Type (2018-2029)

2.3.2 Europe Noninvasive Cancer Diagnostics Revenue Breakdown by Type (2018-2029)

2.3.3 Asia-Pacific Noninvasive Cancer Diagnostics Revenue Breakdown by Type (2018-2029)

2.3.4 Latin America Noninvasive Cancer Diagnostics Revenue Breakdown by Type (2018-2029)

2.3.5 Middle East and Africa Noninvasive Cancer Diagnostics Revenue Breakdown by Type (2018-2029)

3 Noninvasive Cancer Diagnostics Market Overview by Application

3.1 Introduction

3.1.1 Solid Tumors

3.1.2 Blood Cancer

3.1.3 Lung Cancer

3.1.4 Breast Cancer

3.1.5 Others

3.2 Global Noninvasive Cancer Diagnostics Market Size by Application: 2018 VS 2022 VS 2029

3.2.1 Global Noninvasive Cancer Diagnostics Historic Market Size by Application (2018-2023)

3.2.2 Global Noninvasive Cancer Diagnostics Forecasted Market Size by Application (2024-2029)

3.3 Key Regions Market Size by Application

3.3.1 North America Noninvasive Cancer Diagnostics Revenue Breakdown by Application (2018-2029)

3.3.2 Europe Noninvasive Cancer Diagnostics Revenue Breakdown by Application (2018-2029)

3.3.3 Asia-Pacific Noninvasive Cancer Diagnostics Revenue Breakdown by Application (2018-2029)

3.3.4 Latin America Noninvasive Cancer Diagnostics Revenue Breakdown by Application (2018-2029)

3.3.5 Middle East and Africa Noninvasive Cancer Diagnostics Revenue Breakdown by Application (2018-2029)

4 Noninvasive Cancer Diagnostics Competition Analysis by Players

4.1 Global Noninvasive Cancer Diagnostics Market Size by Players (2018-2023)

4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Noninvasive Cancer Diagnostics as of 2022)

4.3 Date of Key Players Enter into Noninvasive Cancer Diagnostics Market

4.4 Global Top Players Noninvasive Cancer Diagnostics Headquarters and Area Served

4.5 Key Players Noninvasive Cancer Diagnostics Product Solution and Service

4.6 Competitive Status

4.6.1 Noninvasive Cancer Diagnostics Market Concentration Rate

4.6.2 Mergers & Acquisitions, Expansion Plans

5 Company (Top Players) Profiles

5.1 Precision Therapeutics, Inc. (U.S.)

5.1.1 Precision Therapeutics, Inc. (U.S.) Profile

5.1.2 Precision Therapeutics, Inc. (U.S.) Main Business

5.1.3 Precision Therapeutics, Inc. (U.S.) Noninvasive Cancer Diagnostics Products, Services and Solutions

5.1.4 Precision Therapeutics, Inc. (U.S.) Noninvasive Cancer Diagnostics Revenue (US$ Million) & (2018-2023)

5.1.5 Precision Therapeutics, Inc. (U.S.) Recent Developments

5.2 A&G Pharmaceutical, Inc. (U.S.)

5.2.1 A&G Pharmaceutical, Inc. (U.S.) Profile

5.2.2 A&G Pharmaceutical, Inc. (U.S.) Main Business

5.2.3 A&G Pharmaceutical, Inc. (U.S.) Noninvasive Cancer Diagnostics Products, Services and Solutions

5.2.4 A&G Pharmaceutical, Inc. (U.S.) Noninvasive Cancer Diagnostics Revenue (US$ Million) & (2018-2023)

5.2.5 A&G Pharmaceutical, Inc. (U.S.) Recent Developments

5.3 Affymetrix Inc. (U.S.)

5.3.1 Affymetrix Inc. (U.S.) Profile

5.3.2 Affymetrix Inc. (U.S.) Main Business

5.3.3 Affymetrix Inc. (U.S.) Noninvasive Cancer Diagnostics Products, Services and Solutions

5.3.4 Affymetrix Inc. (U.S.) Noninvasive Cancer Diagnostics Revenue (US$ Million) & (2018-2023)

5.3.5 AVIVA Biosciences Corporation (U.S.) Recent Developments

5.4 AVIVA Biosciences Corporation (U.S.)

5.4.1 AVIVA Biosciences Corporation (U.S.) Profile

5.4.2 AVIVA Biosciences Corporation (U.S.) Main Business

5.4.3 AVIVA Biosciences Corporation (U.S.) Noninvasive Cancer Diagnostics Products, Services and Solutions

5.4.4 AVIVA Biosciences Corporation (U.S.) Noninvasive Cancer Diagnostics Revenue (US$ Million) & (2018-2023)

5.4.5 AVIVA Biosciences Corporation (U.S.) Recent Developments

5.5 BIOVIEW Inc. (U.S.)

5.5.1 BIOVIEW Inc. (U.S.) Profile

5.5.2 BIOVIEW Inc. (U.S.) Main Business

5.5.3 BIOVIEW Inc. (U.S.) Noninvasive Cancer Diagnostics Products, Services and Solutions

5.5.4 BIOVIEW Inc. (U.S.) Noninvasive Cancer Diagnostics Revenue (US$ Million) & (2018-2023)

5.5.5 BIOVIEW Inc. (U.S.) Recent Developments

5.6 Laboratory Corporation of America Holdings (LabCorp) (U.S.)

5.6.1 Laboratory Corporation of America Holdings (LabCorp) (U.S.) Profile

5.6.2 Laboratory Corporation of America Holdings (LabCorp) (U.S.) Main Business

5.6.3 Laboratory Corporation of America Holdings (LabCorp) (U.S.) Noninvasive Cancer Diagnostics Products, Services and Solutions

5.6.4 Laboratory Corporation of America Holdings (LabCorp) (U.S.) Noninvasive Cancer Diagnostics Revenue (US$ Million) & (2018-2023)

5.6.5 Laboratory Corporation of America Holdings (LabCorp) (U.S.) Recent Developments

5.7 Quest Diagnostics Incorporated Cancer Genetics Inc. (U.S.)

5.7.1 Quest Diagnostics Incorporated Cancer Genetics Inc. (U.S.) Profile

5.7.2 Quest Diagnostics Incorporated Cancer Genetics Inc. (U.S.) Main Business

5.7.3 Quest Diagnostics Incorporated Cancer Genetics Inc. (U.S.) Noninvasive Cancer Diagnostics Products, Services and Solutions

5.7.4 Quest Diagnostics Incorporated Cancer Genetics Inc. (U.S.) Noninvasive Cancer Diagnostics Revenue (US$ Million) & (2018-2023)

5.7.5 Quest Diagnostics Incorporated Cancer Genetics Inc. (U.S.) Recent Developments

5.8 Digene Corporation (U.S.)

5.8.1 Digene Corporation (U.S.) Profile

5.8.2 Digene Corporation (U.S.) Main Business

5.8.3 Digene Corporation (U.S.) Noninvasive Cancer Diagnostics Products, Services and Solutions

5.8.4 Digene Corporation (U.S.) Noninvasive Cancer Diagnostics Revenue (US$ Million) & (2018-2023)

5.8.5 Digene Corporation (U.S.) Recent Developments

5.9 Gen-Probe Incorporated (U.S.)

5.9.1 Gen-Probe Incorporated (U.S.) Profile

5.9.2 Gen-Probe Incorporated (U.S.) Main Business

5.9.3 Gen-Probe Incorporated (U.S.) Noninvasive Cancer Diagnostics Products, Services and Solutions

5.9.4 Gen-Probe Incorporated (U.S.) Noninvasive Cancer Diagnostics Revenue (US$ Million) & (2018-2023)

5.9.5 Gen-Probe Incorporated (U.S.) Recent Developments

5.10 IVDiagnostics, Inc. (U.S.)

5.10.1 IVDiagnostics, Inc. (U.S.) Profile

5.10.2 IVDiagnostics, Inc. (U.S.) Main Business

5.10.3 IVDiagnostics, Inc. (U.S.) Noninvasive Cancer Diagnostics Products, Services and Solutions

5.10.4 IVDiagnostics, Inc. (U.S.) Noninvasive Cancer Diagnostics Revenue (US$ Million) & (2018-2023)

5.10.5 IVDiagnostics, Inc. (U.S.) Recent Developments

6 North America

6.1 North America Noninvasive Cancer Diagnostics Market Size by Country (2018-2029)

6.2 U.S.

6.3 Canada

7 Europe

7.1 Europe Noninvasive Cancer Diagnostics Market Size by Country (2018-2029)

7.2 Germany

7.3 France

7.4 U.K.

7.5 Italy

7.6 Russia

7.7 Nordic Countries

7.8 Rest of Europe

8 Asia-Pacific

8.1 Asia-Pacific Noninvasive Cancer Diagnostics Market Size by Region (2018-2029)

8.2 China

8.3 Japan

8.4 South Korea

8.5 Southeast Asia

8.6 India

8.7 Australia

8.8 Rest of Asia-Pacific

9 Latin America

9.1 Latin America Noninvasive Cancer Diagnostics Market Size by Country (2018-2029)

9.2 Mexico

9.3 Brazil

9.4 Rest of Latin America

10 Middle East & Africa

10.1 Middle East & Africa Noninvasive Cancer Diagnostics Market Size by Country (2018-2029)

10.2 Turkey

10.3 Saudi Arabia

10.4 UAE

10.5 Rest of Middle East & Africa

11 Noninvasive Cancer Diagnostics Market Dynamics

11.1 Noninvasive Cancer Diagnostics Industry Trends

11.2 Noninvasive Cancer Diagnostics Market Drivers

11.3 Noninvasive Cancer Diagnostics Market Challenges

11.4 Noninvasive Cancer Diagnostics Market Restraints

12 Research Finding /Conclusion

13 Methodology and Data Source

13.1 Methodology/Research Approach

13.1.1 Research Programs/Design

13.1.2 Market Size Estimation

13.1.3 Market Breakdown and Data Triangulation

13.2 Data Source

13.2.1 Secondary Sources

13.2.2 Primary Sources

13.3 Disclaimer

13.4 Author List

FEATURED COMPANIES

Precision Therapeutics, Inc. (U.S.)

A&G Pharmaceutical, Inc. (U.S.)

Affymetrix Inc. (U.S.)

BIOVIEW Inc. (U.S.)

Laboratory Corporation of America Holdings (LabCorp) (U.S.)

Quest Diagnostics Incorporated Cancer Genetics Inc. (U.S.)

Digene Corporation (U.S.)

Gen-Probe Incorporated (U.S.)

IVDiagnostics, Inc. (U.S.)

Corporation

List of Tables

Table 1. Global Market Noninvasive Cancer Diagnostics Market Size (US$ Million) Comparison by Region 2018 VS 2022 VS 2029

Table 2. Global Noninvasive Cancer Diagnostics Market Size by Region (2018-2023) & (US$ Million)

Table 3. Global Noninvasive Cancer Diagnostics Market Size Share by Region (2018-2023)

Table 4. Global Noninvasive Cancer Diagnostics Forecasted Market Size by Region (2024-2029) & (US$ Million)

Table 5. Global Noninvasive Cancer Diagnostics Forecasted Market Size Share by Region (2024-2029)

Table 6. Global Noninvasive Cancer Diagnostics Market Size (US$ Million) by Type: 2018 VS 2022 VS 2029

Table 7. Global Noninvasive Cancer Diagnostics Market Size by Type (2018-2023) & (US$ Million)

Table 8. Global Noninvasive Cancer Diagnostics Revenue Market Share by Type (2018-2023)

Table 9. Global Noninvasive Cancer Diagnostics Forecasted Market Size by Type (2024-2029) & (US$ Million)

Table 10. Global Noninvasive Cancer Diagnostics Revenue Market Share by Type (2024-2029)

Table 11. North America Noninvasive Cancer Diagnostics Revenue by Type (2018-2023) & (US$ Million)

Table 12. North America Noninvasive Cancer Diagnostics Revenue by Type (2024-2029) & (US$ Million)

Table 13. Europe Noninvasive Cancer Diagnostics Revenue by Type (2018-2023) & (US$ Million)

Table 14. Europe Noninvasive Cancer Diagnostics Revenue by Type (2024-2029) & (US$ Million)

Table 15. Asia-Pacific Noninvasive Cancer Diagnostics Revenue by Type (2018-2023) & (US$ Million)

Table 16. Asia-Pacific Noninvasive Cancer Diagnostics Revenue by Type (2024-2029) & (US$ Million)

Table 17. Latin America Noninvasive Cancer Diagnostics Revenue by Type (2018-2023) & (US$ Million)

Table 18. Latin America Noninvasive Cancer Diagnostics Revenue by Type (2024-2029) & (US$ Million)

Table 19. Middle East and Africa Noninvasive Cancer Diagnostics Revenue by Type (2018-2023) & (US$ Million)

Table 20. Middle East and Africa Noninvasive Cancer Diagnostics Revenue by Type (2024-2029) & (US$ Million)

Table 21. Global Noninvasive Cancer Diagnostics Market Size (US$ Million) by Application: 2018 VS 2022 VS 2029

Table 22. Global Noninvasive Cancer Diagnostics Market Size by Application (2018-2023) & (US$ Million)

Table 23. Global Noninvasive Cancer Diagnostics Revenue Market Share by Application (2018-2023)

Table 24. Global Noninvasive Cancer Diagnostics Forecasted Market Size by Application (2024-2029) & (US$ Million)

Table 25. Global Noninvasive Cancer Diagnostics Revenue Market Share by Application (2024-2029)

Table 26. North America Noninvasive Cancer Diagnostics Revenue by Application (2018-2023) & (US$ Million)

Table 27. North America Noninvasive Cancer Diagnostics Revenue by Application (2024-2029) & (US$ Million)

Table 28. Europe Noninvasive Cancer Diagnostics Revenue by Application (2018-2023) & (US$ Million)

Table 29. Europe Noninvasive Cancer Diagnostics Revenue by Application (2024-2029) & (US$ Million)

Table 30. Asia-Pacific Noninvasive Cancer Diagnostics Revenue by Application (2018-2023) & (US$ Million)

Table 31. Asia-Pacific Noninvasive Cancer Diagnostics Revenue by Application (2024-2029) & (US$ Million)

Table 32. Latin America Noninvasive Cancer Diagnostics Revenue by Application (2018-2023) & (US$ Million)

Table 33. Latin America Noninvasive Cancer Diagnostics Revenue by Application (2024-2029) & (US$ Million)

Table 34. Middle East and Africa Noninvasive Cancer Diagnostics Revenue by Application (2018-2023) & (US$ Million)

Table 35. Middle East and Africa Noninvasive Cancer Diagnostics Revenue by Application (2024-2029) & (US$ Million)

Table 36. Global Noninvasive Cancer Diagnostics Revenue (US$ Million) by Players (2018-2023)

Table 37. Global Noninvasive Cancer Diagnostics Revenue Market Share by Players (2018-2023)

Table 38. Global Top Players Market Share by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Noninvasive Cancer Diagnostics as of 2022)

Table 39. Date of Key Players Enter into Noninvasive Cancer Diagnostics Market

Table 40. Global Noninvasive Cancer Diagnostics Key Players Headquarters and Area Served

Table 41. Noninvasive Cancer Diagnostics Product Solution and Service

Table 42. Global Noninvasive Cancer Diagnostics Players Market Concentration Ratio (CR5 and HHI)

Table 43. Mergers & Acquisitions, Expansion Plans

Table 44. Precision Therapeutics, Inc. (U.S.) Basic Information List

Table 45. Precision Therapeutics, Inc. (U.S.) Description and Business Overview

Table 46. Precision Therapeutics, Inc. (U.S.) Noninvasive Cancer Diagnostics Products, Services and Solutions

Table 47. Revenue (US$ Million) in Noninvasive Cancer Diagnostics Business of Precision Therapeutics, Inc. (U.S.) (2018-2023)

Table 48. Precision Therapeutics, Inc. (U.S.) Recent Developments

Table 49. A&G Pharmaceutical, Inc. (U.S.) Basic Information List

Table 50. A&G Pharmaceutical, Inc. (U.S.) Description and Business Overview

Table 51. A&G Pharmaceutical, Inc. (U.S.) Noninvasive Cancer Diagnostics Products, Services and Solutions

Table 52. Revenue (US$ Million) in Noninvasive Cancer Diagnostics Business of A&G Pharmaceutical, Inc. (U.S.) (2018-2023)

Table 53. A&G Pharmaceutical, Inc. (U.S.) Recent Developments

Table 54. Affymetrix Inc. (U.S.) Basic Information List

Table 55. Affymetrix Inc. (U.S.) Description and Business Overview

Table 56. Affymetrix Inc. (U.S.) Noninvasive Cancer Diagnostics Products, Services and Solutions

Table 57. Revenue (US$ Million) in Noninvasive Cancer Diagnostics Business of Affymetrix Inc. (U.S.) (2018-2023)

Table 58. Affymetrix Inc. (U.S.) Recent Developments

Table 59. AVIVA Biosciences Corporation (U.S.) Basic Information List

Table 60. AVIVA Biosciences Corporation (U.S.) Description and Business Overview

Table 61. AVIVA Biosciences Corporation (U.S.) Noninvasive Cancer Diagnostics Products, Services and Solutions

Table 62. Revenue (US$ Million) in Noninvasive Cancer Diagnostics Business of AVIVA Biosciences Corporation (U.S.) (2018-2023)

Table 63. AVIVA Biosciences Corporation (U.S.) Recent Developments

Table 64. BIOVIEW Inc. (U.S.) Basic Information List

Table 65. BIOVIEW Inc. (U.S.) Description and Business Overview

Table 66. BIOVIEW Inc. (U.S.) Noninvasive Cancer Diagnostics Products, Services and Solutions

Table 67. Revenue (US$ Million) in Noninvasive Cancer Diagnostics Business of BIOVIEW Inc. (U.S.) (2018-2023)

Table 68. BIOVIEW Inc. (U.S.) Recent Developments

Table 69. Laboratory Corporation of America Holdings (LabCorp) (U.S.) Basic Information List

Table 70. Laboratory Corporation of America Holdings (LabCorp) (U.S.) Description and Business Overview

Table 71. Laboratory Corporation of America Holdings (LabCorp) (U.S.) Noninvasive Cancer Diagnostics Products, Services and Solutions

Table 72. Revenue (US$ Million) in Noninvasive Cancer Diagnostics Business of Laboratory Corporation of America Holdings (LabCorp) (U.S.) (2018-2023)

Table 73. Laboratory Corporation of America Holdings (LabCorp) (U.S.) Recent Developments

Table 74. Quest Diagnostics Incorporated Cancer Genetics Inc. (U.S.) Basic Information List

Table 75. Quest Diagnostics Incorporated Cancer Genetics Inc. (U.S.) Description and Business Overview

Table 76. Quest Diagnostics Incorporated Cancer Genetics Inc. (U.S.) Noninvasive Cancer Diagnostics Products, Services and Solutions

Table 77. Revenue (US$ Million) in Noninvasive Cancer Diagnostics Business of Quest Diagnostics Incorporated Cancer Genetics Inc. (U.S.) (2018-2023)

Table 78. Quest Diagnostics Incorporated Cancer Genetics Inc. (U.S.) Recent Developments

Table 79. Digene Corporation (U.S.) Basic Information List

Table 80. Digene Corporation (U.S.) Description and Business Overview

Table 81. Digene Corporation (U.S.) Noninvasive Cancer Diagnostics Products, Services and Solutions

Table 82. Revenue (US$ Million) in Noninvasive Cancer Diagnostics Business of Digene Corporation (U.S.) (2018-2023)

Table 83. Digene Corporation (U.S.) Recent Developments

Table 84. Gen-Probe Incorporated (U.S.) Basic Information List

Table 85. Gen-Probe Incorporated (U.S.) Description and Business Overview

Table 86. Gen-Probe Incorporated (U.S.) Noninvasive Cancer Diagnostics Products, Services and Solutions

Table 87. Revenue (US$ Million) in Noninvasive Cancer Diagnostics Business of Gen-Probe Incorporated (U.S.) (2018-2023)

Table 88. Gen-Probe Incorporated (U.S.) Recent Developments

Table 89. IVDiagnostics, Inc. (U.S.) Basic Information List

Table 90. IVDiagnostics, Inc. (U.S.) Description and Business Overview

Table 91. IVDiagnostics, Inc. (U.S.) Noninvasive Cancer Diagnostics Products, Services and Solutions

Table 92. Revenue (US$ Million) in Noninvasive Cancer Diagnostics Business of IVDiagnostics, Inc. (U.S.) (2018-2023)

Table 93. IVDiagnostics, Inc. (U.S.) Recent Developments

Table 94. North America Noninvasive Cancer Diagnostics Market Size by Country (2018-2023) & (US$ Million)

Table 95. North America Noninvasive Cancer Diagnostics Market Size by Country (2024-2029) & (US$ Million)

Table 96. Europe Noninvasive Cancer Diagnostics Market Size by Country (2018-2023) & (US$ Million)

Table 97. Europe Noninvasive Cancer Diagnostics Market Size by Country (2024-2029) & (US$ Million)

Table 98. Asia-Pacific Noninvasive Cancer Diagnostics Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2029

Table 99. Asia-Pacific Noninvasive Cancer Diagnostics Market Size by Region (2018-2023) & (US$ Million)

Table 100. Asia-Pacific Noninvasive Cancer Diagnostics Market Size by Region (2024-2029) & (US$ Million)

Table 101. Asia-Pacific Noninvasive Cancer Diagnostics Market Share by Region (2018-2023)

Table 102. Asia-Pacific Noninvasive Cancer Diagnostics Market Share by Region (2024-2029)

Table 103. Latin America Noninvasive Cancer Diagnostics Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2029

Table 104. Latin America Noninvasive Cancer Diagnostics Market Size by Country (2018-2023) & (US$ Million)

Table 105. Latin America Noninvasive Cancer Diagnostics Market Size by Country (2024-2029) & (US$ Million)

Table 106. Middle East & Africa Noninvasive Cancer Diagnostics Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2029

Table 107. Middle East & Africa Noninvasive Cancer Diagnostics Market Size by Country (2018-2023) & (US$ Million)

Table 108. Middle East & Africa Noninvasive Cancer Diagnostics Market Size by Country (2024-2029) & (US$ Million)

Table 109. Noninvasive Cancer Diagnostics Market Trends

Table 110. Noninvasive Cancer Diagnostics Market Drivers

Table 111. Noninvasive Cancer Diagnostics Market Challenges

Table 112. Noninvasive Cancer Diagnostics Market Restraints

Table 113. Research Programs/Design for This Report

Table 114. Key Data Information from Secondary Sources

Table 115. Key Data Information from Primary Sources

List of Figures

Figure 1. Global Noninvasive Cancer Diagnostics Market Size Year-over-Year 2018-2029 & (US$ Million)

Figure 2. Global Noninvasive Cancer Diagnostics Market Size (US$ Million), 2018 VS 2022 VS 2029

Figure 3. Global Noninvasive Cancer Diagnostics Market Share by Regions: 2022 VS 2029

Figure 4. Global Noninvasive Cancer Diagnostics Forecasted Market Size Share by Region (2024-2029)

Figure 5. North America Noninvasive Cancer Diagnostics Market Size Growth Rate (2018-2029) & (US$ Million)

Figure 6. Europe Noninvasive Cancer Diagnostics Market Size Growth Rate (2018-2029) & (US$ Million)

Figure 7. Asia-Pacific Noninvasive Cancer Diagnostics Market Size Growth Rate (2018-2029) & (US$ Million)

Figure 8. Latin America Noninvasive Cancer Diagnostics Market Size Growth Rate (2018-2029) & (US$ Million)

Figure 9. Middle East & Africa Noninvasive Cancer Diagnostics Market Size Growth Rate (2018-2029) & (US$ Million)

Figure 10. Product Picture of Clinical Chemistry

Figure 11. Global Clinical Chemistry Market Size (US$ Million) & YoY Growth (2018-2029)

Figure 12. Product Picture of Immunochemistry/Immunoassay

Figure 13. Global Immunochemistry/Immunoassay Market Size (US$ Million) & YoY Growth (2018-2029)

Figure 14. Product Picture of Molecular Diagnostics

Figure 15. Global Molecular Diagnostics Market Size (US$ Million) & YoY Growth (2018-2029)

Figure 16. Product Picture of Others

Figure 17. Global Others Market Size (US$ Million) & YoY Growth (2018-2029)

Figure 18. Global Noninvasive Cancer Diagnostics Market Size Share by Type: 2022 & 2029

Figure 19. North America Noninvasive Cancer Diagnostics Revenue Market Share by Type (2018-2029)

Figure 20. Europe Noninvasive Cancer Diagnostics Revenue Market Share by Type (2018-2029)

Figure 21. Asia-Pacific Noninvasive Cancer Diagnostics Revenue Market Share by Type (2018-2029)

Figure 22. Latin America Noninvasive Cancer Diagnostics Revenue Market Share by Type (2018-2029)

Figure 23. Middle East and Africa Noninvasive Cancer Diagnostics Revenue Market Share by Type (2018-2029)

Figure 24. Solid Tumors Market Size (US$ Million) & YoY Growth (2018-2029)

Figure 25. Blood Cancer Market Size (US$ Million) & YoY Growth (2018-2029)

Figure 26. Lung Cancer Market Size (US$ Million) & YoY Growth (2018-2029)

Figure 27. Breast Cancer Market Size (US$ Million) & YoY Growth (2018-2029)

Figure 28. Others Market Size (US$ Million) & YoY Growth (2018-2029)

Figure 29. Global Noninvasive Cancer Diagnostics Market Size Share by Application: 2022 & 2029

Figure 30. North America Noninvasive Cancer Diagnostics Revenue Market Share by Application (2018-2029)

Figure 31. Europe Noninvasive Cancer Diagnostics Revenue Market Share by Application (2018-2029)

Figure 32. Asia-Pacific Noninvasive Cancer Diagnostics Revenue Market Share by Application (2018-2029)

Figure 33. Latin America Noninvasive Cancer Diagnostics Revenue Market Share by Application (2018-2029)

Figure 34. Middle East and Africa Noninvasive Cancer Diagnostics Revenue Market Share by Application (2018-2029)

Figure 35. Noninvasive Cancer Diagnostics Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2018 VS 2022

Figure 36. Global Top 5 and Top 10 Players Noninvasive Cancer Diagnostics Market Share in 2022

Figure 37. North America Noninvasive Cancer Diagnostics Market Share by Country (2018-2029)

Figure 38. U.S. Noninvasive Cancer Diagnostics Market Size (2018-2029) & (US$ Million)

Figure 39. Canada Noninvasive Cancer Diagnostics Market Size (2018-2029) & (US$ Million)

Figure 40. Germany Noninvasive Cancer Diagnostics Market Size (2018-2029) & (US$ Million)

Figure 41. France Noninvasive Cancer Diagnostics Market Size (2018-2029) & (US$ Million)

Figure 42. U.K. Noninvasive Cancer Diagnostics Market Size (2018-2029) & (US$ Million)

Figure 43. Italy Noninvasive Cancer Diagnostics Market Size (2018-2029) & (US$ Million)

Figure 44. Russia Noninvasive Cancer Diagnostics Market Size (2018-2029) & (US$ Million)

Figure 45. Nordic Countries Noninvasive Cancer Diagnostics Market Size (2018-2029) & (US$ Million)

Figure 46. Asia-Pacific Noninvasive Cancer Diagnostics Market Share by Region (2018-2029)

Figure 47. China Noninvasive Cancer Diagnostics Market Size (2018-2029) & (US$ Million)

Figure 48. Japan Noninvasive Cancer Diagnostics Market Size (2018-2029) & (US$ Million)

Figure 49. South Korea Noninvasive Cancer Diagnostics Market Size (2018-2029) & (US$ Million)

Figure 50. Southeast Asia Noninvasive Cancer Diagnostics Market Size (2018-2029) & (US$ Million)

Figure 51. India Noninvasive Cancer Diagnostics Market Size (2018-2029) & (US$ Million)

Figure 52. Australia Noninvasive Cancer Diagnostics Market Size (2018-2029) & (US$ Million)

Figure 53. Latin America Noninvasive Cancer Diagnostics Market Share by Country (2018-2029)

Figure 54. Mexico Noninvasive Cancer Diagnostics Market Size (2018-2029) & (US$ Million)

Figure 55. Brazil Noninvasive Cancer Diagnostics Market Size (2018-2029) & (US$ Million)

Figure 56. Middle East & Africa Noninvasive Cancer Diagnostics Market Share by Country (2018-2029)

Figure 57. Turkey Noninvasive Cancer Diagnostics Market Size (2018-2029) & (US$ Million)

Figure 58. Saudi Arabia Noninvasive Cancer Diagnostics Market Size (2018-2029) & (US$ Million)

Figure 59. UAE Noninvasive Cancer Diagnostics Market Size (2018-2029) & (US$ Million)

Figure 60. Bottom-up and Top-down Approaches for This Report

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$3350

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$5025

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$6700

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions